|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/26/20 OncoCyte Corp 10-K 12/31/19 77:37M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 697K
2: EX-4.11 Instrument Defining the Rights of Security Holders HTML 24K
3: EX-10.10 Material Contract HTML 31K
4: EX-10.24 Material Contract HTML 32K
5: EX-10.34 Material Contract HTML 35K
6: EX-10.35 Material Contract HTML 50K
7: EX-10.36 Material Contract HTML 97K
8: EX-21 Subsidiaries List HTML 22K
9: EX-23.1 Consent of Experts or Counsel HTML 24K
10: EX-31 Certification -- §302 - SOA'02 HTML 37K
11: EX-32 Certification -- §906 - SOA'02 HTML 25K
23: R1 Document and Entity Information HTML 61K
60: R2 Balance Sheets HTML 97K
67: R3 Balance Sheets (Parenthetical) HTML 43K
49: R4 Statements of Operations HTML 63K
24: R5 Statements of Comprehensive Loss HTML 35K
61: R6 Statements of Shareholders' Equity HTML 66K
68: R7 Statements of Cash Flows HTML 133K
47: R8 Organization, Description of the Business and HTML 37K
Liquidity
26: R9 Summary of Significant Accounting Policies HTML 80K
58: R10 Selected Balance Sheet Components HTML 41K
70: R11 Related Party Transactions HTML 40K
46: R12 Equity Method Investment in Razor Genomics, Inc. HTML 45K
25: R13 Loan Payable to Silicon Valley Bank HTML 44K
59: R14 Shareholders' Equity HTML 32K
71: R15 Stock-Based Compensation HTML 72K
48: R16 Income Taxes HTML 50K
27: R17 Commitments and Contingencies HTML 66K
62: R18 Subsequent Events HTML 35K
69: R19 Summary of Significant Accounting Policies HTML 136K
(Policies)
35: R20 Summary of Significant Accounting Policies HTML 34K
(Tables)
28: R21 Selected Balance Sheet Components (Tables) HTML 47K
52: R22 Related Party Transactions (Tables) HTML 28K
74: R23 Equity Method Investment in Razor Genomics, Inc. HTML 29K
(Tables)
36: R24 Loan Payable to Silicon Valley Bank (Tables) HTML 29K
29: R25 Stock-Based Compensation (Tables) HTML 70K
53: R26 Income Taxes (Tables) HTML 47K
75: R27 Commitments and Contingencies (Tables) HTML 44K
34: R28 Organization, Description of the Business and HTML 52K
Liquidity (Details Narrative)
30: R29 Summary of Significant Accounting Policies HTML 81K
(Details Narrative)
22: R30 Summary of Significant Accounting Policies - HTML 33K
Schedule of Reconciliation of Cash, Cash
Equivalents, and Restricted Cash (Details)
44: R31 Summary of Significant Accounting Policies - HTML 31K
Common Stock Equivalents Excluded from Computation
of Diluted Net Loss Per Share of Common Stock
(Details)
73: R32 Selected Balance Sheet Components (Details HTML 32K
Narrative)
64: R33 Selected Balance Sheet Components - Schedule of HTML 34K
Prepaid Expenses and Other Current Assets
(Details)
21: R34 Selected Balance Sheet Components - Schedule of HTML 31K
Deposits and Other Noncurrent Assets (Details)
43: R35 Selected Balance Sheet Components - Schedule of HTML 30K
Accrued Expenses and Other Current Liabilities
(Details)
72: R36 Selected Balance Sheet Components - Schedule of HTML 36K
Right of Use Assets, Machinery and Equipment, Net
(Details)
63: R37 Related Party Transactions (Details Narrative) HTML 99K
20: R38 Related Party Transactions - Schedule of Aggregate HTML 36K
Use of Fees Charged (Details)
45: R39 Equity Method Investment in Razor Genomics, Inc. HTML 80K
(Details Narrative)
33: R40 Equity Method Investment in Razor Genomics, Inc. - HTML 53K
Schedule of Condensed Balance Sheet Information
(Details)
39: R41 Loan Payable to Silicon Valley Bank (Details HTML 106K
Narrative)
77: R42 Loan Payable to Silicon Valley Bank - Schedule of HTML 45K
Future Cash Payments of Loan Payable (Details)
55: R43 Shareholders' Equity (Details Narrative) HTML 62K
32: R44 Stock-Based Compensation (Details Narrative) HTML 76K
38: R45 Stock-Based Compensation - Summary of Stock Option HTML 90K
Activity (Details)
76: R46 Stock-Based Compensation - Schdule of Stock HTML 46K
Options Outstanding, Vested and Exercisable
(Details)
54: R47 Stock-Based Compensation - Summary of Stock-based HTML 31K
Compensation Expense (Details)
31: R48 Stock-Based Compensation - Schedule of Assumptions HTML 35K
Used to Calculate Fair Value of Stock Options
(Details)
40: R49 Income Taxes (Details Narrative) HTML 55K
41: R50 Income Taxes - Schedule of Components of Deferred HTML 50K
Tax Assets and Liabilities (Details)
18: R51 Income Taxes - Schedule of Income Tax HTML 49K
Reconciliation (Details)
56: R52 Income Taxes - Schedule of Unrecognized Tax HTML 31K
Benefit (Details)
65: R53 Commitments and Contingencies (Details Narrative) HTML 67K
42: R54 Commitments and Contingencies - Schedule of HTML 31K
Supplemental Cash Flow Information Related to
Operating and Financing Lease (Details)
19: R55 Commitments and Contingencies - Schedule of HTML 45K
Supplemental Balance Sheet Information Related to
Operating and Financing Leases (Details)
57: R56 Commitments and Contingencies - Schedule of Future HTML 70K
Minimum Lease Commitments for Operating and
Financing Leases (Details)
66: R57 Subsequent Events (Details Narrative) HTML 71K
37: XML IDEA XML File -- Filing Summary XML 131K
50: EXCEL IDEA Workbook of Financial Reports XLSX 96K
12: EX-101.INS XBRL Instance -- ocx-20191231 XML 1.15M
14: EX-101.CAL XBRL Calculations -- ocx-20191231_cal XML 197K
15: EX-101.DEF XBRL Definitions -- ocx-20191231_def XML 614K
16: EX-101.LAB XBRL Labels -- ocx-20191231_lab XML 1.15M
17: EX-101.PRE XBRL Presentations -- ocx-20191231_pre XML 855K
13: EX-101.SCH XBRL Schema -- ocx-20191231 XSD 194K
51: ZIP XBRL Zipped Folder -- 0001493152-20-004738-xbrl Zip 166K
Exhibit 10.34
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/16/24 Oncocyte Corp. 10-K 12/31/23 87:30M M2 Compliance LLC/FA 4/12/23 Oncocyte Corp. 10-K 12/31/22 94:11M M2 Compliance LLC/FA 5/02/22 Oncocyte Corp. 10-K/A 12/31/21 12:649K M2 Compliance LLC/FA 3/11/22 Oncocyte Corp. 10-K 12/31/21 90:10M M2 Compliance LLC/FA 4/30/21 OncoCyte Corp. 10-K/A 12/31/20 2:488K M2 Compliance LLC/FA 3/19/21 OncoCyte Corp. 10-K 12/31/20 93:7.4M M2 Compliance LLC/FA |